Navigation Links
SEMBIOSYS ISSUED KEY U.S. PATENT FOR THE PRODUCTION OF APOLIPOPROTEINS IN PLANTS
Date:9/1/2010

uptive technology. It facilitates economical and scalable production of Apo for commercial development, which other drug companies have found difficult and expensive to produce using traditional fermentation methods. This newly patented process makes this drug candidate far more attractive and valuable to a potential pharmaceutical partner for commercial development."

A counterpart to the U.S. patent US 7,786,352 was issued in New Zealand and South Africa, and corresponding patents are pending in many jurisdictions worldwide including Europe, China, Japan, India, Eurasia, Brazil, Australia and Canada.

About SemBioSys

Calgary, Alberta-based SemBioSys is a development stage biotechnology Company that utilizes its patented plant seed oilbody expression technology platforms to develop biosimilar drug candidates and high value proteins. SemBioSys' seed-based protein expression system can enable exceptionally low cost of production with unprecedented scalability and reliability. SemBioSys is focusing the platform selectivity to develop biosimilar product candidates with tremendous commercial value. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AI(Milano), a new chemical entity and next-generation cardiovascular therapy with blockbuster revenue potential if it reaches market for treatment of atherosclerosis. SemBioSys' Apo AI(Milano) is a des-1,2- variant of Apo AI(Milano) as previously described in scientific literature. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking info
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
2. SemBioSys begins phase I/II trial of insulin produced in plant seeds
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. SemBioSys announces senior management changes
5. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
6. SemBioSys provides update on insulin program
7. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
8. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
9. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
10. SemBioSys provides an update on Botaneco
11. SemBioSys announces third quarter 2009 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Eckert & Ziegler Vitalea Science (EZVS), a leading ... pharmaceutical and biotech industry, has announced that Dr. Mark ... of Director of Science & Technology. , “Mark brings ... drug metabolism and bioanalysis to EZVS in both pharma ...
(Date:1/22/2015)... CAMBRIDGE, Mass (PRWEB) January 21, 2015 Cambridge ... Semantic Web technology, today announced that 2014 was a record-breaking ... expanding the capabilities of the Anzo Smart Data Platform and ... discover and utilize insights from diverse data which led to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) ... and 3 chronic hepatitis C - , ... comparable rates of serious adverse events, severe adverse events and ... , ROCKVILLE, Md., Dec. 8 ...
... ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery,products ... the,marketing of the ATS 3f(R) Aortic Bioprosthesis that includes a ... device. , (Logo: ... While the ATS 3f Aortic Bioprosthesis PMA was approved on ...
... databases enable researchers to quickly and effectively use these invaluable resources. ... ... OpenHelix today announced the availability of an updated suite ... Textpresso. Gene Ontology is a consortium project developed to ...
Cached Biology Technology:Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 3New and Updated Online Tutorials for Textpresso and Gene Ontology 2
(Date:12/17/2014)... is fundamentally transforming the travel experience and nowhere is ... past decade, ePassports, biometric readers, and secure document scanners ... control via eGates and Automated Passport Control (APC) Kiosks ... borders across the globe. According to ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... to their offering. One major trend ... biometric systems. Multimodal biometric systems utilize more than one ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... or the answer to your secret question. What,s your dog,s birthday? ... Hoyos Labs , a digital infrastructure security company, launches the ... that comes with usernames, passwords and PINs – 1U TM ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Calif.) Researchers at the UC Davis M.I.N.D. Institute and ... to date describing the medical and psychological characteristics of a ... two "Y" chromosomes, rather than the normal one of each. ... the American Journal of Medical Genetics Part A, ...
... that there is more than one way to grow a biofilm, ... product claims it kills "99 percent" of bacteria, it really does ... bacteria that form on most wet surfaces. They range from the ... sludge that clogs pipes. Most biofilms are harmless, but ...
... available in German . , Together with ... the Center for Allergy and Environment of the Technische ... pinpointed a major gene for allergic diseases. The gene ... whole human genome at the Helmholtz Zentrum Mnchen. The ...
Cached Biology News:UC Davis researchers define characteristics, treatment options for XXYY syndrome 2UC Davis researchers define characteristics, treatment options for XXYY syndrome 3MSU biofilms research helps set standards for everyday products 2Munich researchers discover key allergy gene 2
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... tetrasodium bromide), 50mg/vial. MTT is a pale ... cells to yield a dark blue formazan ... even freshly dead cells do not cleave ... a component of Chemicons MTT assay kit, ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Determin interaction of your protein with Echelons lipids...
Biology Products: